

CIN:U24304GJ2022PLC136193 GST NO.: 24AAQCM2821E1ZN

November 14, 2024

To,
THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
SYMBOL: MONOPHARMA

Dear Sir/Madam,

Sub: Outcome of Board Meeting

This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. With reference to the captioned subject and in furtherance to our intimation letter dated November 6, 2024, we hereby inform the stock exchange that the Board of Directors of the company at its meeting held today i.e. **Thursday, November 14, 2024** inter-alia decided as under:

- 1. Considered and approved Standalone unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2024.
- 2. Considered and approved Consolidated unaudited Financial Results with limited review report of the auditor of the Company for the half year ended September 30, 2024.
- 3. Approved re-constitution of Audit Committee and Stakeholders Relationship Committee. (Attached as "Annexure A")

Kindly note that the meeting of the Board of Directors of the Company commenced at **11:00** a.m. and concluded at **07:18 p.m.**

We request you to kindly take the same on record.

Thanking You,
FOR, MONO PHARMACARE LIMITED

PANILAM

Digitally signed by PANILAM LADVATABIYA

Dit. C-Rit or-Personal postalizades-80058.

4-Gajata.

LAKHATARIYA

3-88 (ECCEPTS-222432CORF20F84F6-31856

6-F. C-PANILAM LADVATAFRIYA

3-68 (ECCEPTS-222432CORF20F84F6-31856)

PANILAM LAKHATARIYA MANAGING DIRECTOR DIN: 07659275

Enclosure: A/a



CIN:U24304GJ2022PLC136193 GST NO.: 24AAQCM2821E1ZN

ANNEXURE- A

Composition of the Committee w.e.f. 14th November, 2024

1. Audit Committee:

Sr.	Name	Designation in the
no.		Committee
1.	Chintan Trivedi (Non-Executive Independent	Chairman
	Director)	
2.	Jitendra Mansukhlal Dasani (Non-Executive	Member
	Independent Director)	
3.	Panilam Lakhatariya (Managing Director)	Member

2. Stakeholders Relationship Committee:

Sr. no.	Name	Designation in the Committee
1.	Jitendra Mansukhlal Dasani (Non-Executive Independent Director)	Chairman
2.	Chintan Trivedi (Non-Executive Independent Director)	Member
3.	Supal Panilam Lakhatariya (Executive Director)	Member

KUMBHAT & CO LLP

Chartered Accountants

812, 8th floor, Corporate Annexe, Sonawala Road, Goregaon (E), Mumbai-400063. Mumbai@kumbhatco.in

Ph.No.022-60600094

Offices at CHENNAI- COIMBATORE - MUMBAI -BANGALORE

Limited Review Report

Review Report to The Board of Directors,

MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ('the Statement') of

MONO PHARMACARE LIMITED ("the Company") for the half year ended September 30, 2024, prepared

and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015. The preparation of the Statement is the

responsibility of the Company's management and has been approved by the Board of Directors of the Company.

Our responsibility is to express a conclusion on the Statement of Unaudited Financial Results based on our

review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of

Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of

Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate

assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries

of company personnel and analytical procedures applied to financial data and thus provide less assurance than

an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the

accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized

accounting practices and policies generally accepted in India, has not disclosed the information required to be

disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it

contains any material misstatement.

For KUMBHAT & CO LLP

Chartered Accountants

Firm Regn. No. S000162/001609S Digitally signed by Gaurang

Champaklal Unadkat

Gaurang Champaklal Unadkat Date: 2024.11.14 18:49:54 +05'30'

Gaurang C. Unadkat

Partner

Mem.No. 131708

UDIN: 24131708BKBIJI1010

Place: Mumbai

Dated: November 14th, 2024

 $Registered\ Office: 1A, Krinkal\ Apartment, Opp. Mahalaxmi\ Temple, Paldi, Ahmedabad, Gujarat, Pin-380007$ CIN:U24304GJ2022PLC136193

Website: www.monopharmacareltd.comEmail: in fo@monopharmacareItd.com

Standalone Statement of Assets and Liabilities as at September 30, 2024

	Particulars	As at September 30th, 2024	(Rs. in Lakhs) As at March 31st 2024 (Audited)
I.	EQUITY AND LIABILITIES	(Unaudited)	2024 (Audited)
(1)	Shareholders' Funds		
	(a) Share Capital	17// 0/	
	(b) Reserve and surplus	1766.86	1766.86
		1273.33	1044.04
(2)	Non-current liabilities	3040.19	2810.90
	(a) Long -term borrowings		
	(b) Long -term Provisions	864.80	433.53
	C C C C C C C C C C C C C C C C C C C	6.79	4.29
(3)	Current Liabilities	871.59	437.82
	(a) Short Term Borrowings		
	(b) Trade Payables	924.25	893.46
	(c) Other Current Liabilities	968.68	291.73
	(d) Short- term Provisions	108.48	79.47
		90.97	26.95
		2092.38	1201.61
	TOTAL EQUITY AND LIABILITES	2072.36	1291.61
	TOTAL EQUIT AND LIABILITES	6004.15	4540.32
	ASSETS		
	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets		
	(ii) Inangible Assets	19.36	12.95
	(iii) Capital WIP	1.17	1.34
	(b) Non-Current Investments	1.80	
		679.94	359.49
	(c) Deferred tax assets (Net)		
	(NI	1.94	1.17
- 1	(d) Long-term loans and advances	1.45	
		1.45	1.45
2)	Current Assets	705.66	376.40
((a) Inventories		070.40
((b) Trade Receivables	2475.44	2099.31
((c) Cash and Cash Equivalents	2595.04	1744.21
- ((d) Short Term Loans and Advances	5.76	25.05
[((e) Other Current Assets	148.74	227.62
	**	73.51	67.72
-		5298.49	4163.92
	TOTAL ASSETS	700.	
		6004.15	4540.32

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya Chairman & Managing Director

DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

 $Registered\ Office: 1A, Krinkal\ Apartment, Opp. Mahalaxmi\ Temple, Paldi, Ahmedabad, Gujarat, Pin-380007$ CIN:U24304GJ2022PLC136193

Website:www.monopharmacareltd.com Email: info@monopharmacareltd.com

Statement of Unaudited Standalone Financial Results for the Half Year ended on September 30,2024

		For t	(Rs. in Lakhs		
	Particulars	September 30, 2024	March 31, 2024	September 30, 2023	March 31,2024
I	Revenue from operation	(Unudited)	(Audited)	(Unudited)	(Audited)
	revenue from operation	4438.32	3612.12	3459.87	7071.9
11	Other income	78.39	91.81	77.84	160.6
Ш	Total Barrers (1 - X)			77.04	169.6
Ш	Total Revenue (I + II)	4516.71	3703.93	3537.71	7241.6
IV	Expenses				721110
	Purchase of Traded Goods				
	(Increase)/Decrease in Stock	4326.19	3474.93	3546.65	7021.5
	Employee Benefits Expenses	-376.13	-130.47	-450.72	-581.1
	Finance Cost	118.74	138.89	105.65	244.:
	Depreciation and Amortisation Cost	59.34	63.67	57.64	121
	Other expenses	3.17	4.12	3.75	7.
	Total Expenses	104.88	87.21	54.68	141.3
		4236.19	3638.35	3317.64	6955.9
V	Profit before tax Extraordinary and Exceptional Items (III - IV)				
	Exceptional Items	280.51	65.59	220.07	285.6
	Extraordinary Items And Tax (V-VI)	0.00	0.00	0.00	0.0
	Prior Period Expenses				
	Profit Before Tax	0.00	0.00	0.00	0.0
	Zerore Tux	280.51	65.59	220.07	285.6
x	Tax Expenses				
	(1) Current Tax				
	(2) Deferred Tax	52.00	-0.80	38.30	37.5
	()	-0.78	8.69	-4.76	3.9
(Profit (Loss) for the Period	220.20			
	- · · · · · · · · · · · · · · · · · · ·	229.29	57.70	186.54	244.2
I	Earning per Equity share:				
	(1) Basic	1.30	0.20		
	(2) Diluted	1.30	0.38	1.43	1.59
		1.30	0.38	1.43	1.59

Notes:

- 1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on November 14 th ,2024 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)
- 2. The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and
- 3. Segment Reporting: The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable. Secondary segmental reporting on the basis of the geographical location of the customers is as below:

		Standa	lone Figures			
					(Rs.in Lakhs)	
		Н	alf Year ended o	n	Year ended on	
Sr.No	Particulars	Sept 30, 2024	March 31, 2024	Sept 30, 2023	March 31, 2024	
				, , , , , , ,		
1	India	4438.32	3603.71	3459.87	7050	
2	Rest of the World			3439.67	7063.58	
			8.41	-	8.41	
	Total	4438.32	2542.45			
		4430.32	3612.12	3459.87	7071.99	

- 4. The information presented above is extracted from the unaudited Standalone Financial Statements for the Half-ended September 30th, 2024, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the
- 5. The figures for the preceding half year ended on 31st March, 2024 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2024 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors.

- 6. The company came with an Initial Public Offer of equity shares on 28th Aug., 2023 and closed on August 30,2023. The initial public offer ("IPO") was for 53,00,000 equity shares of face value of Rs. 10 each at premium of Rs. 18 per share aggregating to INR 1484.00 lakhs. The shares of the company were listed on the National Stock Exchange of India Limited, Emerge Platform on September 7, 2023
- 7. The details of utilization of IPO Proceeds are as per the table set forth below:

S. No.	Particulars	Projected Utilization of proceeds as per prospectus	Utilization of proceeds upto	Pending for Utilization of proceeds upto 30-
1	Working Capital Requirements			09-2024
2	General Corporate Purpose	898.00	898.00	-
-		366.00	252.16	113.84
	Issue expenses	220.00	220.00	
	Total Proceeds from the Issue			
		1484.00	1370.16	113.84

- 8. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com
- 9. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya Chairman & Managing Director

DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

Registered Office:1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007 CIN:U24304GJ2022PLC136193

Website:www.monopharmacareltd.com Email: info@monopharmacareltd.com

Standalone Cash Flow statement as at September 30,2024

(Rs. in Lakhs)

Cash flow from operating activities 2024 (Unaudited) 2024 (Audited) Profit/(loss) before tax 280.51 285.6 Non-cash adjustments to reconcile profit before tax to net cash flows 3.17 7.8 Depreciation 3.17 7.8 Finance Cost 50.34 121.3 Operating profit/(loss) before working capital changes 343.03 414.8 Movements in working capital: 676.95 82.4 Increase/(decrease) in trade payables 676.95 82.4 Increase/(decrease) in short term provision 676.95 82.4 Increase/(decrease) in short term provision 676.95 82.4 Increase/(decrease) in short term borrowings 30.79 -13.5 Decrease/(increase) in Inventories 30.79 -13.5 Decrease/(increase) in Inventories 350.83 -581.1 Decrease/(increase) in Inventories 750.84 -81.0 Decrease/(increase) in short-term loans and advances 78.88 81.0 Decrease/(increase) in other Current Assets -5.78 4.14.4 Lass Direct taxes paid -5.00 -37.50			(Rs. in Lakhs)			
Penfit/(loss) before tax Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustments to reconcile profit before tax to net eash flows Non-cash adjustment to net eash flows Non-cash						
Non-eash adjustments to reconcile profit before tax to net cash flows	Cash flow from operating activities					
Non-cash adjustments to reconcile profit before tax to net cash flows 3.17 7.8 7.8 7.3 7.8 7.3	Profit/(loss) before tax	280.51	285.67			
Finance Cost	Non-cash adjustments to reconcile profit before tax to net cash flows	200.31	283.00			
Finance Cost	Depreciation	3 17	7.0-			
A						
Movements in working capital: Increase/(decrease) in trade payables 676.95 82.4 Increase/(decrease) in short term provision 29.01 17.5 Increase/(decrease) in short term provision 64.02 -17.9 Increase/(decrease) in short term porrowings 30.79 -13.5 Decrease/(increase) in Inventories 376.13 -581.1 Decrease/(increase) in Inventories -376.13 -581.1 Decrease/(increase) in Inventories -850.83 -935.8 81.0 Decrease/(increase) in short-term loans and advances 78.88 81.0 Decrease/(increase) in short-term loans and advances -5.78 -41.4 Decrease/(increase) in other Current Assets -7.5 -7.5 -4.1 Decrease/(increase) in other Current Assets -10.06 -994.1 Decrease/(increase) in cash and cash equivalents (B) -331.65 -465.94 Decrease/(increase) in cash and cash equivalents (C) -30.00 -30.00 Decrease/(increase) in cash and cash equivalents (C) -39.00 Decrease/(increase) in cash and cash equivalents (C) -19.20 Decrease/(increase) in cash	Operating profit/(loss) before working capital changes					
Increase/(decrease) in other current liabilities	Movements in working capital:	343.03	414.0			
Increase/(decrease) in other current liabilities	Increase/(decrease) in trade payables	676.05	92.40			
Increase/(decrease) in short term provision	Increase/(decrease) in other current liabilities					
Increase/(decrease) in short term borrowings 30.79 -13.51 Decrease/(increase) in Inventories 37.61 3 -581.11 Decrease/(increase) in Inventories .78.81 .78.81 Decrease/(increase) in other Current Assets .78.88 .81.0 Decrease/(increase) in other Current Assets .79.00 .79.00 Decrease/(increase) in cash and cash equivalents (A+B+C) .79.29 .79.20 Decrease/(increase) in cash and cash equivalents (A+B+C) .79.20 .79.20 Decrease/(increase) in cash and cash equivalents at the edgining of the year .79.00 .79.00 Decrease/(increase) in cash and cash equivalents at the edgining of the year .79.00 .79.00 Decrease/(increase) in cash and cash equivalents at the edgining of the year .79.00 .79.00 Decrease/(increase) in cash and cash equivalents at the edgining of the year .79.00 .79.00 Decrease/(increase) in cash and cash equivalents at the edgining of the year .79.00 .79.00 Decrease/(increase) in cash and c	Increase/(decrease) in short term provision					
Decrease/(increase) in Inventories 337.13 5.158.11 Decrease/(increase) in trade receivables .850.83 .935.83 Decrease/(increase) in other Current Assets .850.83 .935.83 Decrease/(increase) in other Current Assets .5.78 .41.41 Destrease/(increase) in other Current Assets .5.78 .41.42 Destrease/(increase) in other Current Assets .5.78 .41.43 Destrease/(increase) in other Current Assets .5.78 .41.44 Destrease/(increase) in other Current Assets .5.78 .41.43 Destrease/(increase) in other Current Assets .5.78 .41.44 Destrease/(increase) in other Current Assets .5.78 .41.44 Destrease/(increase) in other Current Assets .5.78 .41.44 Destrease/(increase) in other Current Assets .5.76 .5.84 Destrease/(increase) in o	Increase/(decrease) in short term borrowings					
Decrease/(increase) in trade receivables	Decrease/(increase) in Inventories					
Decrease/(increase) in short-term loans and advances 78.88 81.00 78.88 81.00 78.88 81.00 78.88 81.00 78.88 81.00 78.88 81.00 79.38 78.88 81.00 79.38	Decrease/(increase) in trade receivables					
Decrease/(increase) in other Current Assets	Decrease/(increase) in short-term loans and advances					
Cash generated from Operations -10.06 -394.11 Less: Direct taxes paid -52.00 -37.50 Cash from Operating Activities (A) -62.00 -1031.64 Cash flows from investing activities Cash flows from investing activities Cash flow from investing activities Cash flow from investing activities Cash flow from/(used in) investing activities (B) -331.65 -165.94 Cash flow from/(used in) investing activities (B) -331.65 -165.94 Cash flow from financing activities Cash flow from	Decrease/(increase) in other Current Assets					
Cash from Operating Activities (A) -52.00 -37.50 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.06 -1031.64 -62.07 -30.00 -62.08 -30.04 -162.94 -62.08 -30.04 -162.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.08 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.09 -331.65 -165.94 -62.00 -331.65	Cash generated from Operations					
Cash flow from investing activities Cash flow from/(used in) investing activities (B) Cash flow from/(used in) investing activities (B) Cash flow from financing activities Cash flow from/(used in) financing activities (C) Cash flow from/(used in) financi						
Sale/(Purchase) of Fixed Assets -11.21 -3.00	Net Cash from Operating Activities (A)		-37.50 - 1031.64			
Sale/(Purchase) of Fixed Assets -11.21 -3.00	Cash flows from investing activities					
Purchase of Investment -320.44 -162.94 Idet cash flow from/(used in) investing activities (B) -331.65 -165.94 Idet cash flow from/(used in) investing activities (B) -331.65 -165.94 Idet cash flow from financing activities (B) -331.65 -165.94 Idet cash flow from financing activities (B) -331.65 -165.94 Idet cash flow from financing activities (B) -331.65 -165.94 Idet cash flow from financing activities (B) -331.65 -165.94 Idet cash flow from financing activities (B) -331.65 -165.94 Idet cash flow from financing activities (C) -30.00 Idet cash flow from/(used in) financing activities (C) -257.26 Idet cash flow from/(used in) financing activities (C) -19.29 -19.78 Idet cash flow from/(used in) financing activities (C) -19.29 -19.78 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -19.29 -19.29 Idet cash flow from/(used in) financing activities (C) -	Sale/(Purchase) of Fixed Assets	11.21				
Let cash flow from/(used in) investing activities (B) Cash flow from financing activities Acceptance / (Repayment) of Long Term Loan ayment / (Repayment) of Long term Loan advance ong term Provision rocceds from issue of equity shares ecurities Premium on Allotment of Equity Shares ecurities Premium on Allotment of Equity Shares on tilised for IPO Expenses inance Cost et cash flow from/(used in) financing activities (C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents et increase/(decrease) in cash and cash equivalents -165.94 431.26 90.05 90.05 90.00 0.00 0.00 0.00 954.00 954.00 0.00 0.257.26 -59.34 -121.31 -199.78 2199 2.19	Purchase of Investment	l l				
Cash flow from financing activities Acceptance / (Repayment) of Long Term Loan ayment / (Repayment) of Long term Loan advance ong term Provision roceeds from issue of equity shares ecurities Premium on Allotment of Equity Shares certifies Premium on Allotment of Equity Shares titlised for IPO Expenses inance Cost et cash flow from/(used in) financing activities (C) et increase/(decrease) in cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents	Net cash flow from/(used in) investing activities (B)	331 65				
Acceptance / (Repayment) of Long Term Loan ayment / (Repayment) of Long term Loan advance ong term Provision roceeds from issue of equity shares ecurities Premium on Allotment of Equity Shares filised for IPO Expenses inance Cost et cash flow from/(used in) financing activities (C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents et increase/(decrease) in cash and cash equivalents 431.26 90.05 90.00 0.00 0.00 0.00 0.00 0.00 0.	Cash flow from financing activities	-531.05	-165.94			
ayment / (Repayment) of Long term Loan advance ong term Provision roceeds from issue of equity shares ecurities Premium on Allotment of Equity Shares (tilised for IPO Expenses inance Cost et cash flow from/(used in) financing activities (C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents 431.26 90.05 0.00 0.00 0.00 530.00 954.00 -257.26 -59.34 -121.31 1199.78 2.19 2.19 2.19 2.19 2.86 et increase/(decrease) in cash and cash equivalents 5.76 25.05						
ong term Provision roceeds from issue of equity shares ecurities Premium on Allotment of Equity Shares (1,00) (1,0	Payment / (Renayment) of Long term Loan	431.26	90.05			
roceeds from issue of equity shares ecurities Premium on Allotment of Equity Shares (tilised for IPO Expenses inance Cost et cash flow from/(used in) financing activities (C) et increase/(decrease) in cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents 2.50 4.29 5.30.00 530.00 54.00 5257.26 593.4 51199.78 519.29 2.19 2.19 2.19 2.19 2.19 2.19 2.19 2.19 2.19 2.19 2.10 2		0.00	0.00			
ecurities Premium on Allotment of Equity Shares (1) 00		2.50	4.29			
titilised for IPO Expenses inance Cost 10,00	Securities Premium on Alletment of Fauity Charge	0.00	530.00			
inance Cost 10,00 -257.26 1-59.34 -121.31 et cash flow from/(used in) financing activities (C) 374.42 1199.78 et increase/(decrease) in cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents 25.05 22.86 et increase/(decrease) in cash and cash equivalents	Itilised for IPO Expenses	0.00	954.00			
tet cash flow from/(used in) financing activities (C) at cash flow from/(used in) financing activities (C) at increase/(decrease) in cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year at increase/(decrease) in cash and cash equivalents 5.76 25.05		0.00	-257.26			
et increase/(decrease) in cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents 25.05 22.86 et increase/(decrease) in cash and cash equivalents		-59.34	-121.31			
et increase/(decrease) in cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year et increase/(decrease) in cash and cash equivalents 5.76 25.05	set cash flow from/(used in) financing activities (C)	374,42	1199 78			
ash and cash equivalents at the beginning of the year ash and cash equivalents at the end of the year 25.05 et increase/(decrease) in cash and cash equivalents 5.76 25.05	let increase/(decrease) in cash and cash equivalents (A+B+C)		1177.78			
ash and cash equivalents at the end of the year 25.05 22.86 et increase/(decrease) in cash and cash equivalents 5.76 25.05		-19.29	2.19			
et increase/(decrease) in cash and cash equivalents	ash and cash equivalents at the beginning of the year	25.05	22.07			
to the case (decrease) in cash and cash equivalents	asn and cash equivalents at the end of the year					
	et increase/(decrease) in cash and cash equivalents					

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya Chairman & Managing Director DIN: 07659275

Place: Ahmedabad Date: November 14th, 2024 KUMBHAT & CO LLP **Chartered Accountants**

812, 8th floor, Corporate Annexe, Sonawala Road, Goregaon (E), Mumbai-400063. Mumbai@kumbhatco.in Ph.No.022-60600094

Offices at CHENNAI- COIMBATORE - MUMBAI -BANGALORE

Limited Review Report

Review Report to The Board of Directors,

MONO PHARMACARE LIMITED

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ('the Statement') of

MONO PHARMACARE LIMITED ("the Parent") ("the Company") and its Subsidiary Company for the half

year ended September 30, 2024, prepared and being submitted by the Company pursuant to the requirement of

Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The preparation

of the Statement is the responsibility of the Company's management and has been approved by the Board of

Directors of the Company. Our responsibility is to express a conclusion on the Consolidated Statement of

Unaudited Financial Results based on our review.

We conducted our review in accordance with the Standard on Review Engagement-(SRE) 2410, on "Review of

Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of

Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate

assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries

of company personnel and analytical procedures applied to financial data and thus provide less assurance than an

audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the

accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised

accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains

any material misstatement.

For KUMBHAT & CO LLP

Chartered Accountants Firm Regn. No. S000162/001609S

Digitally signed by Gaurang

Gaurang Champaklal

Champaklal Unadkat

Date: 2024.11.14 **Unadkat**

18:51:51 +05'30'

Gaurang C. Unadkat

Partner

Mem.No. 131708

UDIN: 24131708BKBIJG8181

Place: Mumbai

Dated: November 14th, 2024

 $Registered\ Office: 1A, Krinkal\ Apartment, Opp. Mahalaxmi\ Temple, Paldi, Ahmedabad, Gujarat, Pin-380007$

CIN:U24304GJ2022PLC136193 Website:www.monopharmacareltd.com Email: info@monopharmacareltd.com

Consolidated Statement of Assets and Liabilities as at September 30th,2024

(Rs. in Lakhs)

	•		(NS. III Lakiis)
Sr.No.	Particulars	As at September 30,2024 (Unaudited)	As at March 31,2024 (Audited)
I.	EQUITY AND LIABILITIES	30,2024 (Chaudited)	31,2024 (Audited)
(1)	Shareholders' Funds		
	(a) Share Capital	1769.55	1768.80
	(b) Reserve and surplus	1270.64	1042.10
(2)	Minority Interest	2.69	1.94
		3042.88	2812.84
(3)	Non-current liabilities		
` '	(a) Long -term borrowings	2191.62	1712.49
	(b) Long -term Provision	6.79	4.29
		2198.41	1716.78
(4)	Current Liabilities		
	(a) Short Term Borrowings	2679.47	2431.55
	(b) Trade Payables	1728.81	968.51
	(c) Other Current Liabilities	135.74	119.35
	(d) Short- term Provisions	166.28	62.25
		4710.30	3581.66
	TOTAL EQUITY AND LIABILITES	9951.59	8111.27
II.	ASSETS		0111127
(1)	Non Current Assets		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	97.25	89.90
	(ii) Intangible Assets	1.17	1.34
	(iii) Capital Work In Progress	1.80	-
	(b) Non-Current Investments	-	-
	(c) Deferred tax assets (Net)	1.94	1.17
280	(d) Long-term loans and advances	2.50	2.50
		104.66	94.91
(2)	Current Assets	20 1.00	94.91
	(a) Inventories	4774.31	4229.26
	(b) Trade Receivables	4584.24	3159.03
	(c) Cash and Cash Equivalents	13.11	
	(d) Short Term Loans and Advances	360.49	36.27 471.49
	(e) Other Current Assets	114.77	120.32
		9846.92	8016.36
	TOTAL ACCEPTA		
	TOTAL ASSETS	9951.59	8111.27

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya Chairman & Managing Directo

DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024

Registered Office:1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007 CIN:U24304GJ2022PLC136193

Website:www.monopharmacareltd.com Email: info@monopharmacareltd.com

Statement of Unaudited Consolidated Financials Results for the Half Year ended on September 30 th,2024

Rs. in Lakt

					(Rs. in Lakhs
Sr.No.	Particulars	Santania 20 2024			For the year ended
01.1.10.	Tar ucular s	September 30,2024	March 31,2024	September 30,2023	March 31,2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operation	8716.28	5580.90	6653.12	12234.02
II	Other income	4.27	6.04	3.50	9.54
III	Total Revenue (I + II)	8720.55	5586.94	6656.62	12243.50
IV	Expenses				
	Purchase of Traded Goods	0.400.00			S . 89/-0
	(Increase)/Decrease in Stock	8480.82	5415.91	6612.34	12028.25
	Employee Benefits Expenses	-545.06	-378.35	-582.30	-960.65
	Finance Cost	170.21	170.10	181.29	351.39
	Depreciation and Amortisation Cost	156.31	158.63	149.67	308.29
	Other expenses	6.42	6.42	5.11	11.52
	Total Expenses	136.64	127.47	54.68	182.15
	Total Expenses	8405.34	5500.18	6420.78	11920.95
V VI	Profit before tax Extraordinary and Exceptional Items (III - IV)	315.21	86.76	235.85	322.60
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Extraordinary Items And Tax (V-VI)				
	Prior Period Expenses	0.00	0.00		2.89
VIII	Profit Before Tax	315.21		0.00	0.00
		313.21	86.76	235.85	322.60
IX	Tax Expenses				
	(1) Current Tax	85.95	19.50	53.30	72.80
	(2) Deferred Tax	0.78	8.69	-4.76	3.92
				-4.70	3.92
X	Profit (Loss) for the Year	230.04	58.57	187.31	245.88
XI	M	0.75			210.00
XI	Minority Interest	-0.75	-0.88	-0.77	-1.65
	Profit/(Loss) for the year after Taxes				
XII	and Minority Interest	229.29	57.70	186.54	244.24
XIII	Earning per Equity share:			1000	- / 11.2 1
	(1) Basic	1.30	0.38		
	(2) Diluted	1.30		1.43	1.58
	(2) Diluted	1.30	0.38	1.43	1

Notes:

- 1. The above results were reviewed and recommended by the Audit Committee, at its meeting held on 14th November, 2024 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The above consolidated financial result include two subsidiary firms wherein the company holds 99% of the partner's capital of M/s. Ahmedabad Medical Corporation and M/s. Supal Distributors LLP.
- 3.Segment Reporting: The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable.Secondary segmental reporting on the basis of the geographical location of the customers is as below:

	Consolidated Figures						
	(Rs.in Lakhs						
Sr.			Half Year ended o	n	Year ended on		
No	Particulars	Sept 30, 2024	March 31, 2024	Sept 30, 2023	March 31, 2024		
					•		
1	India	8716.28	5580.90	6653.12	12225.61		
2	Rest of the World	-	8.41	-	8.41		
	Total	8716.28	5589.31	6653.12	12234.02		

- 4. The information presented above is extracted from the unaudited Consolidated Financial Statements for the Half-ended September 30th, 2024, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.
- 5. The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2024, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.
- 6. The figures for the preceding half year ended on 31st March, 2024 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2024 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors.
- 7. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com
- 8. Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya Chairman & Managing Director DIN: 07659275

Place: Ahmedabad Date: November 14th, 2024

Registered Office:1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007 CIN:U24304GJ2022PLC136193

Website:www.monopharmacareltd.com Email: in fo@monopharmacareltd.com

Consolidated Statement of Cash Flow as at September 30, 2024

Particulars		(Rs. in Lakh	
	As at September	As at March 31,2024	
Cash flow from operating activities	30,2024 (Unaudited)	(Audited)	
custing activities			
Profit/(loss) before tax			
Non-cash adjustments to reconcile profit before tax to net cash flows	315.21	322.	
Depreciation			
Finance Cost	6.42	11.	
	156.31	308.	
Operating profit/(loss) before working capital changes Movements in working capital:	477.94	642.	
Increase/(decrease) in trade payables		042.	
Increase/(decrease) in trade payables	760.30	292.	
Increase/(decrease) in other current liabilities	16.39	1.1	
Increase/(decrease) in short term provision	104.03	-13.	
Increase/(decrease) in short term borrowings	247.92	182.	
Decrease/(increase) in Inventories	-545.06	-960.	
Decrease/(increase) in trade receivables	-1425.22	-960.6 -971.9	
Decrease/(increase) in short-term loans and advances	111.00		
Decrease/(increase) in other Current Assets	5.55	63.1	
Cash generated from Operations	-247.14	-41.0	
Less: Direct taxes paid	-85.95	-804.1	
Net Cash from Operating Activities (A)	-333.09	-73.(
Sala a constant	-555.09	-877.1	
Cash flows from investing activities			
Sale/(Purchase) of Fixed Assets	-13.60	17.6	
Purchase of Investment	0.00	-17.5	
	0.00	57.3	
et cash flow from/(used in) investing activities (B)	-13.60	20.0	
	-13.00	39.8	
ash flow from financing activities			
Acceptance / (Repayment) of Long Term Loan	479.13	nn -	
acrease/(Decrease) in Long term Provision	2.50	-88.5.	
crease in Share Capital	2.30	#2.1 o	
crease in Security Premium		531.9	
crease/(Decrease) in Capital Work In Progress	-1.80	696.7	
nance Cost	-156.31	200.0	
	-130.31	-308.29	
et cash flow from/(used in) financing activities (C)	323.52	831.84	
et increase/(decrease) in cash and cash equivalents (A+B+C)	22.14		
	-23.16	-5.50	
ish and cash equivalents at the beginning of the year	36.27	41.77	
ish and cash equivalents at the end of the year	13.11	36.27	
et increase/(decrease) in cash and cash equivalents	-23.16	-5.50	

For and on behalf of the Board of Directors Mono Pharmacare Limited (Chy oran

Panilam S. Lakhatariya Chairman & Managing Director

DIN: 07659275

Place: Ahmedabad

Date: November 14th, 2024.